Edward R. Hagen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Edward R. Hagen has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Amber May
Swedish Medical Center, First Hill Campus, Department of Pediatrics, Pediatric Hospitalists, 1101 Madison St #800, Seattle, WA, 98104, USA
1 shared publication - Amir Loucas Bastawrous
Swedish Cancer Institute, Seattle, USA
1 shared publication - Gerson
Swedish Medical Center, Colon & Rectal Clinic, Seattle, WA, USA
1 shared publication - John A. Griffin
Swedish Medical Center, Seattle, USA
1 shared publication Laila Rashidi
Multicare, Colon & Rectal Surgery, Tacoma, WA, USA
1 shared publication- Mansen Wang
Medical Data Research Center, Providence St. Joseph Health, 9427 SW Barnes Road, Suite 594, Portland, OR, 97225, USA
1 shared publication
Latest Publications
- 14 April 2021
- Published by Elsevier in The American Journal of Surgery
- Vol. 221 (6) , 1291-1292
Robotic surgical management of sigmoid colon cancer in pregnancy: A case series
- 14 April 2021
- Published by Elsevier in The American Journal of Surgery
- Vol. 221 (6) , 1291-1292
Robotic surgical management of sigmoid colon cancer in pregnancy: A case series
- 1 April 2021
- Published by Elsevier in The American Journal of Surgery
- Vol. 221 (4) , 850-855
Post operative pediatric appendicitis nurse-driven discharge: Patient outcomes and nursing perspectives
- 1 April 2021
- Published by Elsevier in The American Journal of Surgery
- Vol. 221 (4) , 850-855
Post operative pediatric appendicitis nurse-driven discharge: Patient outcomes and nursing perspectives
- 1 September 2020
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
- Vol. 63 (9) , 1185-1189
Organ Preservation in the Treatment of Stage II and III Rectal Cancer
CASE SUMMARY: A 65-year-old man underwent colonoscopy to evaluate rectal bleeding and was found to have a low rectal mass. Biopsy revealed moderately differentiated microsatellite stable adenocarcinoma. The tumor was palpable at the fingertip in the anterior rectum with the inferior border 5 cm from the anal verge by rigid proctoscopy. CEA was 0.8 ng/mL. CT imaging of the chest, abdomen, and pelvis showed no evidence of distant metastases. MRI confirmed a 5-cm mass with one 8-mm mesorectal lymph node metastasis and no extramural venous invasion. The tumor penetrated the mesorectal fat to a depth of 4 mm, and the circumferential margin was estimated to be 1 mm from the tumor (Fig. 1). He was presented at the multidisciplinary tumor board conference and interviewed and examined at the multidisciplinary clinic. He was dismayed at the prospect of his surgical options, a low anterior resection versus abdominoperineal resection, and wished to keep the options for organ preservation available. Standard long-course chemoradiation was initiated, with resolution of his bleeding after 2 weeks. He then completed 6 cycles of folinic acid, fluorouracil, and oxaliplatin (FOLFOX) chemotherapy (consolidation total neoadjuvant therapy (TNT)). The tumor was no longer palpable on office examination. A complete clinical response (cCR) was confirmed by flexible sigmoidoscopy (Fig. 2) and MRI (Fig. 3). He was entered into the nonoperative management program with intense surveillance scheduling and has no evidence of recurrent disease almost 2 years after completion of TNT.
- 1 September 2020
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
- Vol. 63 (9) , 1185-1189
Organ Preservation in the Treatment of Stage II and III Rectal Cancer
CASE SUMMARY: A 65-year-old man underwent colonoscopy to evaluate rectal bleeding and was found to have a low rectal mass. Biopsy revealed moderately differentiated microsatellite stable adenocarcinoma. The tumor was palpable at the fingertip in the anterior rectum with the inferior border 5 cm from the anal verge by rigid proctoscopy. CEA was 0.8 ng/mL. CT imaging of the chest, abdomen, and pelvis showed no evidence of distant metastases. MRI confirmed a 5-cm mass with one 8-mm mesorectal lymph node metastasis and no extramural venous invasion. The tumor penetrated the mesorectal fat to a depth of 4 mm, and the circumferential margin was estimated to be 1 mm from the tumor (Fig. 1). He was presented at the multidisciplinary tumor board conference and interviewed and examined at the multidisciplinary clinic. He was dismayed at the prospect of his surgical options, a low anterior resection versus abdominoperineal resection, and wished to keep the options for organ preservation available. Standard long-course chemoradiation was initiated, with resolution of his bleeding after 2 weeks. He then completed 6 cycles of folinic acid, fluorouracil, and oxaliplatin (FOLFOX) chemotherapy (consolidation total neoadjuvant therapy (TNT)). The tumor was no longer palpable on office examination. A complete clinical response (cCR) was confirmed by flexible sigmoidoscopy (Fig. 2) and MRI (Fig. 3). He was entered into the nonoperative management program with intense surveillance scheduling and has no evidence of recurrent disease almost 2 years after completion of TNT.
- Open Access
- 1 July 2020
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2020 (7) , rjaa151
Perianal basal cell carcinoma: a common cancer in an uncommon location
This is a case of a perianal basal cell carcinoma, a common skin cancer in an unusual location. Our patient is a 67-year-old male with a perianal lesion. He first noticed this painless lesion 5 years prior to presentation and was having fecal incontinence and weight loss. He had a fully encompassing ulcerated lesion involving the entirety of the anal margin. We performed a biopsy that returned on pathology as a basal cell carcinoma. Due to the size of the lesion and his current nutritional status, it was determined to be unresectable. We were able to provide him with a diverting colostomy to address his incontinence and this allowed the patient to recover enough to undergo treatment with radiation (total of 5400 cGy). To our knowledge, this is the largest perianal basal cell carcinoma reported in the literature and an example of combining palliative surgery and radiation as a treatment option.
- 1 July 2020
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2020 (7) , rjaa151
Open AccessPerianal basal cell carcinoma: a common cancer in an uncommon location
This is a case of a perianal basal cell carcinoma, a common skin cancer in an unusual location. Our patient is a 67-year-old male with a perianal lesion. He first noticed this painless lesion 5 years prior to presentation and was having fecal incontinence and weight loss. He had a fully encompassing ulcerated lesion involving the entirety of the anal margin. We performed a biopsy that returned on pathology as a basal cell carcinoma. Due to the size of the lesion and his current nutritional status, it was determined to be unresectable. We were able to provide him with a diverting colostomy to address his incontinence and this allowed the patient to recover enough to undergo treatment with radiation (total of 5400 cGy). To our knowledge, this is the largest perianal basal cell carcinoma reported in the literature and an example of combining palliative surgery and radiation as a treatment option.